News & Updates

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.

Negative upper endoscopy findings in patients with gastroesophageal reflux disease (GERD) indicate lower risk of developing upper gastrointestinal cancer, a new study has found.

Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.

Treatment with calcifediol shortly after hospitalization with COVID-19 results in a significant reduction in intensive care unit (ICU) admission and death by more than 50 percent, reveals a study. In addition, baseline 25(OH)D levels is negatively associated with both ICU admission and mortality.

Smartwatches, with the support of machine learning algorithms, can perceive face-touching (FT) behaviours and may help contain outbreaks of respiratory infections such as the coronavirus disease 2019 (COVID-19), according to a new study.

Primary percutaneous coronary intervention (pPCI) is as good as conservative management in terms of the benefit for in-hospital mortality among ST-segment elevation myocardial infarction (STEMI) patients receiving maintenance dialysis, a study has found.